uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Vise andre og tillknytning
2015 (engelsk)Inngår i: Cell Death and Disease, ISSN 2041-4889, E-ISSN 2041-4889, Vol. 6, artikkel-id e1794Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Two main causes of platinum resistance are mutation in the tumor suppressor gene TP53 and drug-induced increase in intracellular glutathione concentration. Mutations in TP53 occur in about 50% of human tumors. APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 and induces apoptosis. APR-246 is a prodrug that is converted to the active compound methylene quinuclidinone (MQ), a Michael acceptor that binds to cysteine residues in mutant p53 and restores its wildtype conformation. Here, we show that MQ also binds to cysteine in glutathione, thus decreasing intracellular free glutathione concentration. We also show that treatment with APR-246 completely restores the cisplatin and doxorubicin sensitivity to p53-mutant drug-resistant ovarian cancer cells. We propose that this unique ability of APR-246/MQ to bind to cysteines in both mutant p53 and glutathione has a key role in the resensitization as well as in the outstanding synergistic effects observed with APR-246 in combination with platinum compounds in ovarian cancer cell lines and primary cancer cells. However, MQ binding to cysteines in other targets, for example, thioredoxin reductase, may contribute as well. Strong synergy was also observed with the DNA-damaging drugs doxorubicin and gemcitabine, while additive effects were found with the taxane docetaxel. Our results provide a strong rationale for the ongoing clinical study with APR-246 in combination with platinum-based therapy in patients with p53-mutant recurrent high-grade serous (HGS) ovarian cancer. More than 96% of these patients carry TP53 mutations. Combined treatment with APR-246 and platinum or other DNA-damaging drugs could allow dramatically improved therapy of a wide range of therapy refractory p53 mutant tumors.

sted, utgiver, år, opplag, sider
2015. Vol. 6, artikkel-id e1794
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-259117DOI: 10.1038/cddis.2015.143ISI: 000357514700020PubMedID: 26086967OAI: oai:DiVA.org:uu-259117DiVA, id: diva2:843337
Tilgjengelig fra: 2015-07-28 Laget: 2015-07-27 Sist oppdatert: 2017-12-04bibliografisk kontrollert

Open Access i DiVA

fulltext(1802 kB)269 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1802 kBChecksum SHA-512
a9fda1b52bb74ffcc7e88f9b1b7c7d081711a698fffd8b8e9755da186631a4aaa5026e8068e8846dac4c7c99899088b06002c296e2768938361ecab909871691
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Gullbo, JoachimHallberg, Anders

Søk i DiVA

Av forfatter/redaktør
Gullbo, JoachimHallberg, Anders
Av organisasjonen
I samme tidsskrift
Cell Death and Disease

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 269 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 726 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf